A MULTI-CENTER OPEN LABEL PHASE 1/2 STUDY OF CYT-0851 AN ORAL RAD51 INHIBITOR IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES AND ADVANCED SOLID TUMORS
Brief description of study
The purpose of the study to determine the safety of CYT-0851 in patients with relapsed/refractory B-Cell malignancies and advanced solid tumors. The study drug CYT-0851 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.
Clinical Study Identifier: s20-00047
ClinicalTrials.gov Identifier: NCT03997968
Principal Investigator:
Nina Beri.
Other Investigators:
Joshua K Sabari,
Janice Mehnert,
Ann M Riccobene,
Cosmin Adrian Tegla,
Jessica Wang,
Zujun Li,
Salman Rafi Punekar,
Nora Russo,
Christy Lynn Spalink,
Kristen Spencer,
Nila Theresa De La Rosa,
Avital Benson,
Kathleen M Madden,
Christina Grace Wilson,
Elaine Shum,
Douglas K Marks,
Maya Dimitrova,
Scot Niglio,
Sally Lau,
Keriann M Scavone,
Bhavana Pothuri,
Elise M Zahriah,
Carol M Lee,
Maryann J Kwa,
Kathleen M Lutz,
Jonathan B Kahn,
Vamsidhar Velcheti.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
